Malin, Jakob J. and Spinner, Christoph D. and Janssens, Uwe and Welte, Tobias and Weber-Carstens, Steffen and Schaelte, Gereon and Gastmeier, Petra and Langer, Florian and Wepler, Martin and Westhoff, Michael and Pfeifer, Michael and Rabe, Klaus F. and Hoffmann, Florian and Bottiger, Bernd W. and Weinmann-Menke, Julia and Kersten, Alexander and Berlit, Peter and Krawczyk, Marcin and Nehls, Wiebke and Fichtner, Falk and Laudi, Sven and Stegemann, Miriam and Skoetz, Nicole and Nothacker, Monika and Marx, Gernot and Karagiannidis, Christian and Kluge, Stefan (2022) Key summary of German national treatment guidance for hospitalized COVID-19 patients Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021). INFECTION, 50 (1). pp. 93-106. ISSN 0300-8126, 1439-0973
Full text not available from this repository. (Request a copy)Abstract
Purpose This executive summary of a national living guideline aims to provide rapid evidence based recommendations on the role of drug interventions in the treatment of hospitalized patients with COVID-19. Methods The guideline makes use of a systematic assessment and decision process using an evidence to decision framework (GRADE) as recommended standard WHO (2021). Recommendations are consented by an interdisciplinary panel. Evidence analysis and interpretation is supported by the CEOsys project providing extensive literature searches and living (meta-) analyses. For this executive summary, selected key recommendations on drug therapy are presented including the quality of the evidence and rationale for the level of recommendation. Results The guideline contains 11 key recommendations for COVID-19 drug therapy, eight of which are based on systematic review and/or meta-analysis, while three recommendations represent consensus expert opinion. Based on current evidence, the panel makes strong recommendations for corticosteroids (WHO scale 5-9) and prophylactic anticoagulation (all hospitalized patients with COVID-19) as standard of care. Intensified anticoagulation may be considered for patients with additional risk factors for venous thromboembolisms (VTE) and a low bleeding risk. The IL-6 antagonist tocilizumab may be added in case of high supplemental oxygen requirement and progressive disease (WHO scale 5-6). Treatment with nMABs may be considered for selected inpatients with an early SARS-CoV-2 infection that are not hospitalized for COVID-19. Convalescent plasma, azithromycin, ivermectin or vitamin D-3 should not be used in COVID-19 routine care. Conclusion For COVID-19 drug therapy, there are several options that are sufficiently supported by evidence. The living guidance will be updated as new evidence emerges.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | VENOUS THROMBOEMBOLISM; PREVENTION; PLACEBO; IVERMECTIN; PNEUMONIA; EFFICACY; SAFETY; COVID-19; SARS-CoV-2; Living guideline; Living meta-analysis |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin II |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 04 Oct 2022 07:16 |
| Last Modified: | 04 Oct 2022 07:16 |
| URI: | https://pred.uni-regensburg.de/id/eprint/48187 |
Actions (login required)
 |
View Item |
